CDH1 and breast cancer: Of the 280 women who tested negative for BRCA1/2 PGVs, 134 (47.9%) had sufficient DNA available for extended panel testing of at least ATM, CDH1, CHEK2, NBN, PALB2, PTEN, RAD50, RAD51D, and TP53. This resulted in the detection of an additional 13 PGVs of which 10 (7.46%) could be considered to be actionable with at least a confirmed two fold increased breast cancer risk [21] (4 in ATM, 1 in CDH1, 1 in CHEK2, 2 in PALB2, and 2 in TP53) (Table 1).